Patents by Inventor Deborah A. Lannigan-Macara

Deborah A. Lannigan-Macara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis and identification of novel RSK-specific inhibitors
    Patent number: 9040673
    Abstract: A composition comprising an SL0101 [kaempferol 3-O-(3?,4?-di-O-acetyl-?-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell.
    Type: Grant
    Filed: August 13, 2010
    Date of Patent: May 26, 2015
    Assignee: University of Virginia Patent Foundation
    Inventors: Sidney M. Hecht, Deborah A. Lannigan-Macara, Jeffrey Allan Smith, George A. O'Doherty, Michael Kenneth Hilinski
  • Rhamnose substituents of SL0101 and therapeutic uses thereof
    Patent number: 8426568
    Abstract: The present invention provides compositions and methods useful for preparing and using analogs, derivatives, and modifications of kaempferols that have anti-neoplastic activity. More specifically, the compounds are analogs, derivatives, and modifications of SLO1O1. The invention further provides compounds that are inhibitors of rsk activity. The invention further provides compounds that selectively inhibit excessive rsk activity in cancers. The present invention further provides methods for treating cancer using compounds of the invention.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: April 23, 2013
    Assignee: University of Virginia Patent Foundation
    Inventors: Jeffrey A. Smith, Sidney M. Hecht, Deborah A. Lannigan-Macara, David J. Maloney
  • SYNTHESIS AND IDENTIFICATION OF NOVEL RSK-SPECIFIC INHIBITORS
    Publication number: 20120245112
    Abstract: A composition comprising an SL0101 [kaempferol 3-O-(3?,4?-di-O-acetyl-?-L-rhamnopyranoside)] derivative compound that has enhanced ability to inhibit RSK activity, relative to the parent compound is provided. The compounds have utility for treating any disease or conditions characterized or associated with excess or undesirable RSK activity. For example the RSK inhibitors of the present invention can be used to reduce the proliferation of neoplastic cells or for inhibiting the establishment or maintenance of an intracellular pathogenic infection by pathogens whose pathogenicity derives in part from the pathogen's ability to impede endosomal/phagosomal maturation in the host cell.
    Type: Application
    Filed: August 13, 2010
    Publication date: September 27, 2012
    Inventors: Sidney M. Hecht, Deborah A. Lannigan-Macara, Jeffrey Allan Smith, George A. O'doherty, Michael Kenneth Hilinski
  • RHAMNOSE SUBSTITUENTS OF SL0101 AND THERAPEUTIC USES THEREOF
    Publication number: 20100016245
    Abstract: The present invention provides compositions and methods useful for preparing and using analogs, derivatives, and modifications of kaempferols that have anti-neoplastic activity. More specifically, the compounds are analogs, derivatives, and modifications of SLO1O1. The invention further provides compounds that are inhibitors of rsk activity. The invention further provides compounds that selectively inhibit excessive rsk activity in cancers. The present invention further provides methods for treating cancer using compounds of the invention.
    Type: Application
    Filed: May 22, 2007
    Publication date: January 21, 2010
    Applicant: University of Virginia Patent Foundation
    Inventors: Jeffrey A. Smith, Sidney M. Hecht, Deborah A. Lannigan-Macara, David J. Maloney
  • Rsk inhibitors and therapeutic uses thereof
    Publication number: 20070049539
    Abstract: The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.
    Type: Application
    Filed: September 20, 2006
    Publication date: March 1, 2007
    Inventors: Jeffrey Smith, Deborah Lannigan-Macara, Celeste Poteet-Smith, Sidney Hecht, Yaming Xu, David Brautigan
  • Erk7 and erk8, novel diagnostic markers for cancer
    Publication number: 20060141473
    Abstract: The present invention is directed in part to the discovery of a novel signal transduction pathway that regulates estrogen responsiveness. Human extracellular signal-regulated kinase 8 (ERK8) has been discovered by applicants to preferentially enhance the destruction of ER?, and loss of ERK8 is correlated with breast cancer progression. Thus monitoring the expression of ERK8 can be used as a diagnostic and therapeutic indicator of cancer and cancer progression.
    Type: Application
    Filed: June 17, 2004
    Publication date: June 29, 2006
    Inventors: Deborah Lannigan-Macara, Lorin Henrich, Jeffrey Smith
  • Rsk inhibitors and therapeutic uses thereof
    Publication number: 20050233985
    Abstract: The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.
    Type: Application
    Filed: June 12, 2003
    Publication date: October 20, 2005
    Inventors: Jeffrey Smith, Deborah Lannigan-Macara